Zahl des Monats3,8

Sidebar menu

Gesamtverzeichnis

  • 1

    21.10.2020

    Learnings from Regional Market Dynamics of Originator and Biosimilar Infliximab and Etanercept in Germany

    ; Moorkens, E. ; Barcina Lacosta, T. ; Vulto, A. ; Schulz, M. ; Gradl, G. ; Enners, S. ; Selke, G. ; Huys, I. ; Simoens, S.

    Pharmaceuticals 2020, 13, 324
    doi:10.3390/ph13100324

    Link zur Publikation

    Conflicts of interest: S.S., I.H. and A.G.V. have founded the KU Leuven Fund on Market Analysis of Biologics and Biosimilars following Loss of Exclusivity (MABEL). S.S. was involved in a stakeholder roundtable on biologics and biosimilars sponsored by Amgen, Pfizer and MSD; he has participated in advisory board meetings for Pfizer and Amgen; he has contributed to studies on biologics and biosimilars for Hospira (together with A.G.V. and I.H.), Celltrion, Mundipharma and Pfizer, and he has had speaking engagements for Amgen and Sandoz. A.G.V. is involved in consulting, advisory work and speaking engagements for a number of companies, a.o. AbbVie, Accord, Amgen, Biogen, EGA, Pfizer/Hospira, Mundipharma, Roche, Sandoz. E.M., T.B.L., G.G., S.E., M.S. and G.S. declare no conflict of interest.

  • 1

    19.10.2020

    Impact of angiotensin receptor blocker product recalls on antihypertensive prescribing in Germany

    ; Rudolph, U. ; Enners, S. ; Kieble, M. ; Mahfoud, F. ; Böhm, M. ; Laufs, U. ; Schulz, M.

    J Hum Hypertens, 14.10.2020
    doi.org./10.1038/s41371-020-00425-z 

    Conflicts of interest: UR has received scientific support and speaker honoraria from Bayer, Berlin Chemie, and Bristol Myers Squibb, all outside the submitted work. FM is supported by Deutsche Gesellschaft für Kardiologie (DGK) and has received scientific support and speaker honoraria from Bayer, Boehringer Ingelheim, Medtronic, and ReCor Medical, all outside the submitted work. FM and MB are supported by the Deutsche Forschungsgemeinschaft (SFB TRR219). UL has received speaker honoraria from Bayer, Boehringer Ingelheim, Novartis and Servier, all outside the submitted work. MS has received speaker honoraria from Novartis and Sanofi, all outside the submitted work. All other authors declare no conflict of interest.

  • 1

    08.10.2020

    “Dear Doctor” Warning Letter (Rote-Hand-Brief) on Hydrochlorothiazide and Its Impact on Antihypertensive Prescription

    ; Mahfoud, F. ; Kieble, M. ; Enners, S. ; Werning, J. ; Laufs, U. ; Millenaar, D. ; Böhm, M. ; Kintscher, U. ; Schulz, M.

    Dtsch Arztebl Int 2020; 117: 687–8.
    DOI: 10.3238/arztebl.2020.0687

    Link zur Publikation

    Conflicts of interest: Felix Mahfoud erhielt Forschungsunterstützung und Vortragshonorare von Medtronic, Recor, Berlin Chemie und Boehringer Ingelheim. Michael Böhm bekam Honorare für Beratertätigkeit von den Firmen Abott, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Servier, Medtronic, Vifor, Novartis und Bristol Myers Squibb. Ulrich Kintscher erhielt Forschungsunterstützung und/oder Vortraghonorare von Bayer, Berlin Chemie, Boehringer Ingelheim, Daiichi Sankyo, Novartis, Sanofi und Servier. Ulrich Laufs hat Vortragshonorare von Bayer, Boehringer Ingelheim, Novartis und Servier erhalten. Martin Schulz bekam Vortragshonorare von Novartis und Sanofi. Die übrigen Autoren erklären, dass kein Interessenkonflikt besteht.

Hinweis: Für die Ansicht der PDF Dokumente wird der Acrobat Reader benötigt. Klicken Sie auf die Grafik, um ihn herunterzuladen.